Vaxart Inc Stock EBITDA
| VXRT Stock | USD 0.61 0.01 1.67% |
Vaxart Inc fundamentals help investors to digest information that contributes to Vaxart's financial success or failures. It also enables traders to predict the movement of Vaxart Stock. The fundamental analysis module provides a way to measure Vaxart's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaxart stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -74.7 M | -71 M |
Vaxart | EBITDA |
Vaxart Inc Company EBITDA Analysis
Vaxart's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Vaxart EBITDA | (74.72 M) |
Most of Vaxart's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaxart Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vaxart EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Vaxart is extremely important. It helps to project a fair market value of Vaxart Stock properly, considering its historical fundamentals such as EBITDA. Since Vaxart's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vaxart's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vaxart's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Vaxart Ebitda
Ebitda |
|
According to the company disclosure, Vaxart Inc reported earnings before interest,tax, depreciation and amortization of (74.72 Million). This is 108.52% lower than that of the Biotechnology sector and 174.61% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.92% higher than that of the company.
Vaxart EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxart's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxart could also be used in its relative valuation, which is a method of valuing Vaxart by comparing valuation metrics of similar companies.Vaxart is currently under evaluation in ebitda category among its peers.
Vaxart Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vaxart from analyzing Vaxart's financial statements. These drivers represent accounts that assess Vaxart's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vaxart's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.5M | 504.2M | 761.5M | 122.6M | 83.0M | 139.5M | |
| Enterprise Value | (3.7M) | 384.5M | 630.8M | 100.3M | 74.7M | 127.8M |
Vaxart Institutional Holders
Institutional Holdings refers to the ownership stake in Vaxart that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vaxart's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vaxart's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 186.6 K | Bank Of America Corp | 2024-06-30 | 166.2 K | Monaco Asset Management | 2024-09-30 | 164.3 K | Qube Research & Technologies | 2024-06-30 | 163.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 153.5 K | Xtx Topco Ltd | 2024-09-30 | 136.5 K | Two Sigma Investments Llc | 2024-09-30 | 111.1 K | Simplex Trading, Llc | 2024-06-30 | 98.3 K | Group One Trading, Lp | 2024-06-30 | 84.4 K | Sio Capital Management, Llc | 2024-09-30 | 13.6 M | Vanguard Group Inc | 2024-09-30 | 10.1 M |
Vaxart Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (2.54) % | ||||
| Current Valuation | 95.98 M | ||||
| Shares Outstanding | 227.48 M | ||||
| Shares Owned By Insiders | 0.87 % | ||||
| Shares Owned By Institutions | 17.80 % | ||||
| Number Of Shares Shorted | 11.27 M | ||||
| Price To Book | 1.99 X | ||||
| Price To Sales | 9.80 X | ||||
| Revenue | 7.38 M | ||||
| Gross Profit | (80.95 M) | ||||
| EBITDA | (74.72 M) | ||||
| Net Income | (82.47 M) | ||||
| Cash And Equivalents | 129.55 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 26.51 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 8.65 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (70.45 M) | ||||
| Short Ratio | 11.71 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Target Price | 4.83 | ||||
| Number Of Employees | 109 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 136.49 M | ||||
| Total Asset | 91.83 M | ||||
| Retained Earnings | (409.57 M) | ||||
| Working Capital | 31.81 M | ||||
| Net Asset | 91.83 M |
About Vaxart Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaxart Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxart using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxart Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.